Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:44:18 EDT Tue 30 Apr 2024
Enter Symbol
or Name
USA
CA



Z:JNJ - JOHNSON & JOHNSON - http://www.jnj.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JNJ - Z5.0145.58·145.613.5145.60-1.22-0.82,241.9322,55335,338146.73  146.75  145.35175.97  143.1311:27:57Apr 2215 min RT 2¢

Recent Trades - Last 10 of 35338
Time ETExPriceChangeVolume
11:28:07Z145.5891-1.23091
11:28:07Z145.59-1.231
11:28:06Z145.58-1.241
11:28:06Z145.58-1.241
11:28:06Z145.58-1.241
11:28:06Z145.58-1.243
11:28:06Z145.58-1.241
11:28:05Z145.5891-1.230912
11:28:04Z145.595-1.2253
11:28:03Z145.5924-1.22761

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-22 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)
2024-04-20 01:28U:JNJSEDAR Annual ReportSEDAR MD & A
2024-04-16 06:25U:JNJNews ReleaseJohnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
2024-04-16 03:20U:JNJNews ReleaseCORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
2024-04-08 18:06U:JNJNews ReleaseJohnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
2024-04-05 23:21U:JNJNews ReleaseCARVYKTI(TM) is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
2024-04-05 06:31U:JNJNews ReleaseJohnson & Johnson to Acquire Shockwave Medical
2024-04-04 18:01U:JNJNews ReleaseJohnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation
2024-04-02 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the BofA Securities Health Care Conference
2024-03-12 09:15U:JNJNews ReleaseArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
2024-03-11 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on First-Quarter Results
2024-03-07 08:33U:JNJNews ReleaseJohnson & Johnson Completes Acquisition of Ambrx
2024-03-01 15:59U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2024-02-20 16:26U:JNJNews ReleaseTECVAYLI ‚ ® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
2024-02-14 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
2024-02-12 16:10U:JNJNews ReleaseJohnson & Johnson to Participate in the Leerink Global Biopharma Conference
2024-02-02 16:10U:JNJNews ReleaseJohnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
2024-01-24 15:42U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-01-23 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q4 and Full-Year 2023 Results
2024-01-08 07:30U:JNJNews ReleaseJohnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer